Tumor necrosis factor-alpha
Jump to navigation
Jump to search
In medicine, tumor necrosis factor-alpha is a "serum glycoprotein produced by activated macrophages and other mammalian mononuclear leukocytes. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to tnf-beta (lymphotoxin), but they share TNF receptors.[1]
Tumor necrosis factor inhibitors
- TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of TNF-alpha.[2] Etanercept is used for the treatment of autoimmune diseases such as ankylosing spondylitis.[3]
- Infliximab (pronounced in flix' i mab)is a chimeric monoclonal antibody that blocks the action of TNF-alpha by binding to it.[4]
Adverse effects
Tumor necrosis factor inhibitors increase susceptibility to serious infections.[5]
References
- ↑ Anonymous (2024), Tumor necrosis factor-alpha (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Template:MedMaster
- ↑ Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
- ↑ Template:MedMaster
- ↑ Anonymous (2008). FDA MedWatch - 2008 Safety Alerts for Human Medical Products. U.S. Food and Drug Administration.